Can a transplant drug stop COVID lung damage?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years of age * Approval from the patient's primary inpatient service * Hospitalized * Diagnosed with COVID-19 pneumonia * Positive test for active SARS-CoV-2 infection * Requiring supplemental oxygen ≥ 5LNC or ≥ 40% FiO2. * Chest computed tomography (CT) at admission with \< 10% pulmonary fibrosis * Ability to provide written informed consent on the part of the subject or, in the absence of decisional capacity of the subject, an appropriate surrogate (e.g. a legally authorized representative). Exclusion Criteria: * Known diagnosis of previous pulmonary fibrosis or an interstitial lung disease. * Clinical features or known diagnosis of malignancy or active non-COVID-19 infection, including untreated latent tuberculosis. * History of unstable or deteriorating cardiac disease (including myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia. * Known history of hypersensitivity to sirolimus. * History of unstable or deteriorating neurologic disease (including TIAs or stroke). * Pregnant or lactating females. Females of child bearing potential are required to have a negative pregnancy test prior to treatment and practice abstinence or prevent pregnancy by at least a barrier method of birth control. * Investigational therapy for any indication within 28 days prior to treatment. * Current treatment with any drugs that are strong inhibitors of CYP3A4. * Tofacitinib * Clarithromycin * Telithromycin * Nefazodone * Itraconazole * Ketoconazole * Atazanavir * Darunavir * Indinavir * Lopinavir * Nelfinavir * Ritonavir * Saquinavir * Tipranavir. * Inability or unwillingness to comply with the requirements for the trial.